Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T‐cell subsets and inflammatory cytokines

References

• Jonsson R., Bolstad A. I., Brokstad K. A., Brun J. G. Sjögren's syndrome – a plethora of clinical and immunological phenotypes with a complex genetic background. Ann N Y Acad Sci 2007; 1108: 433–47
   PubMed Web of Science ®Google Scholar
• Garberg H., Jonsson R., Brokstad K. A. The serological pattern of autoantibodies to the Ro52, Ro60, and La48 autoantigens in primary Sjögren's syndrome patients and healthy controls. Scand J Rheumatol 2005; 34: 49–55
   PubMed Web of Science ®Google Scholar
• Zeher M., Adany R., Nagy G., Gomez R., Szegedi G. Macrophage containing factor XIII subunit a in salivary glands of patients with Sjögren's syndrome. J Invest Allergol Clin Immunol 1991; 1: 261–5
   PubMed Web of Science ®Google Scholar
• Zeher M., Szodoray P., Gyimesi E., Szondy Z. Correlation of increased susceptibility to apoptosis of CD4+ T cells with lymphocyte activation and activity of disease in patients with primary Sjögren's syndrome. Arthritis Rheum 1999; 42: 1673–81
   PubMed Web of Science ®Google Scholar
• Manthorpe R., Bredberg A., Henriksson G., Larsson A. Progress and regression within primary Sjögren's syndrome. Scand J Rheumatol 2006; 35: 1–6
   PubMed Web of Science ®Google Scholar
• Lotz M. K. Cytokines and their receptors. Arthritis and allied conditions, Textbook of rheumatology, 14th edn, W. J Koopman. Lippincott Williams & Wilkins, Philadelphia 2001; 436–77
   Google Scholar
• Garcíc‐Carrasco M., Font J., Filella X., Cervera R., Ramos‐Casals M., Sisó A., et al. Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 2001; 19: 411–15
   PubMed Web of Science ®Google Scholar
• Bombardieri M., Barone F., Pittoni V., Alessandri C., Conigliaro P., Blades M. C., et al. Increased circulating levels and salivary gland expression of interleukin‐18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther 2004; 6: R447–56
   PubMed Web of Science ®Google Scholar
• Perrier S., Serre A. F., Dubost J. J., Beaujon G., Plazonnet M. P., Albuisson E., Sauvezie B., et al. Increased serum levels of interleukin 10 in Sjögren's syndrome: correlation with increased IgG1. J Rheumatol 2000; 27: 935–9
   PubMed Web of Science ®Google Scholar
• Sfriso P., Ostuni P., Botsios C., Andretta M., Oliviero F., Punzi L., Todesco S., et al. Serum and salivary neopterin and interferon‐gamma in primary Sjögren's syndrome. Correlation with clinical, laboratory and histopathologic features. Scand J Rheumatol 2003; 32: 74–8
   PubMed Web of Science ®Google Scholar
• Anaya J. M., Correa P. A., Herrera M., Eskdale J., Gallagher G. Interleukin 10 (IL‐10) influences autoimmune response in primary Sjögren's syndrome and is linked to IL‐10 gene polymorphism. J Rheumatol 2002; 29: 1874–6
   PubMed Web of Science ®Google Scholar
• Konttinen Y. T., Kemppinen P., Koski H., Li T. F., Jumppanen M., Hietanen J., Santavirta S., et al. T(H)1 cytokines are produced in labial salivary glands in Sjögren's syndrome, but also in healthy individuals. Scand J Rheumatol 1999; 28: 106–12
   PubMed Web of Science ®Google Scholar
• Mitsias D. I., Tzioufas A. G., Veiopoulou C., Zintzaras E., Tassios I. K., Kogopoulou O., et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren's syndrome. Clin Exp Immunol 2002; 128: 562–8
   PubMed Web of Science ®Google Scholar
• Szodoray P., Alex P., Brun J. G., Centola M., Jonsson R. Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 2004; 59: 592–9
   PubMed Web of Science ®Google Scholar
• Marka M., Bessenyei B., Zeher M., Semsei I. IL‐10 promoter –1082 polymorphism is associated with elevated IL‐10 levels in control subjects but does not explain elevated plasma IL‐10 observed in Sjögren's syndrome in a Hungarian cohort. Scand J Immunol 2005; 62: 474–80
   PubMed Web of Science ®Google Scholar
• Bertorello R., Cordone M. P., Contini P., Rossi P., Indiveri F., Puppo F., et al. Increased levels of interleukin‐10 in saliva of Sjögren's syndrome patients. Correlation with disease activity. Clin Exp Med 2004; 4: 148–51
   PubMed Web of Science ®Google Scholar
• Font J., García‐Carrasco M., Ramos‐Casals M., Aldea A. I., Cervera R., Ingelmo M., et al. The role of interleukin‐10 promoter polymorphisms in the clinical expression of primary Sjögren's syndrome. Rheumatology (Oxford) 2002; 41: 1025–30
   PubMed Web of Science ®Google Scholar
• Ramos‐Casals M., García‐Carrasco M., Cervera R., Filella X., Trejo O., de la Red G., et al. Th1/Th2 cytokine imbalance in patients with Sjögren syndrome secondary to hepatitis C virus infection. Semin Arthritis Rheum 2002; 32: 56–63
   PubMed Web of Science ®Google Scholar
• Pertovaara M., Antonen J., Hurme M. Th2 cytokine genotypes are associated with a milder form of primary Sjögren's syndrome. Ann Rheum Dis 2006; 65: 666–70
   PubMedGoogle Scholar
• Halse A., Tengner P., Wahren‐Herlenius M., Haga H., Jonsson R. Increased frequency of cells secreting interleukin‐6 and interleukin‐10 in peripheral blood of patients with primary Sjögren's syndrome. Scand J Immunol 1999; 49: 533–8
   PubMed Web of Science ®Google Scholar
• Gottenberg J. E., Busson M., Loiseau P., Dourche M., Cohen‐Solal J., Lepage V., et al. Association of transforming growth factor beta1 and tumor necrosis factor alpha polymorphisms with anti‐SSB/La antibody secretion in patients with primary Sjögren's syndrome. Arthritis Rheum 2004; 50: 570–80
   PubMed Web of Science ®Google Scholar
• Hooks J. J., Moutsopoulos H. M., Geis S. A., Stahl N. I., Decker J. L., Notkins A. L., et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5–8
   PubMed Web of Science ®Google Scholar
• Hjelmervik T. O., Petersen K., Jonassen I., Jonsson R., Bolstad A. I. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum 2005; 52: 1534–44
   PubMed Web of Science ®Google Scholar
• Gottenberg J. E., Lavie F., Abbed K., Gasnault J., Le Nevot E., Delfraissy J. F., et al. CD4CD25 high regulatory T cells are not impaired in patients with primary Sjögren's syndrome. J Autoimmun 2005; 24: 235–42
   PubMed Web of Science ®Google Scholar
• Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H. M., Alexander E. L., Carsons S. E., et al. European Study Group on Classification Criteria for Sjögren's Syndrome: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 2002; 61: 554–8
   PubMed Web of Science ®Google Scholar
• Bodolay E., Aleksza M., Antal‐Szalmás P., Végh J., Szodoray P., Soltész P., et al. Serum cytokine levels and type 1 and type 2la intracellular T cell cytokine profiles in mixed connective tissue disease. J Rheumatol 2002; 29: 2136–42
   PubMedGoogle Scholar
• Anand A., Dean G. S., Quereshi K., Isenberg D. A., Lydyard P. M. Characterization of CD3+ CD4– CD8– (double negative) T cells in patients with systemic lupus erythematosus: activation markers. Lupus 2002; 11: 493–500
   PubMed Web of Science ®Google Scholar
• Ortaldo J. R., Winkler‐Pickett R. T., Yagita H., Young H. A. Comparative studies of CD3– and CD3+CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore‐forming protein expression. Cell Immunol 1991; 136: 486–95
   PubMed Web of Science ®Google Scholar
• Ferrini S., Cambiaggi A., Meazza R., Sforzini S., Marciano S., Mingari M. C., et al. T cell clones expressing the natural killer cell‐related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function. Eur J Immunol 1994; 24: 2294–8
   PubMedGoogle Scholar
• Mingari M. C., Vitale C., Cambiaggi A., Schiavetti F., Melioli G., Ferrini S., et al. Cytolitic T lymphocytes displaying natural killer (NK)‐like activity. Expression of NK‐related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR‐mediated target cell lysis or lymphokine production. Int Immunol 1995; 7: 697–703
   PubMedGoogle Scholar
• Skold M., Faizunnessa N. N., Wang C. R., Cardell S. CD1d‐specific NK1.1+ T cells with transgenic variant TCR. J Immunol 2000; 165: 168–74
   PubMedGoogle Scholar
• Chiu Y. H., Jayawardena J., Weiss A., Lee D., Park S. H., Dautry‐Varsat A., et al. Distinct subsets of CD1d‐restricted T cells recognize self‐antigens loaded in different cellular compartments. J Exp Med 1999; 189: 103–10
   PubMed Web of Science ®Google Scholar
• Chen H., Paul W. E. Cultured NK1.1+CD4+ T cells produce large amounts of IL‐4 and IFN‐gamma upon activation by anti‐CD3 or CD1. J Immunol 1997; 159: 2240–9
   PubMed Web of Science ®Google Scholar
• Doherty D. G., Norris S., Madrigal‐Estebas L., McEntee G., Traynor O., Hegarty J. E., et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 1999; 163: 2314–21
   PubMed Web of Science ®Google Scholar
• Mendes R., Bromelow K. V., Westby M., Galea‐Lauri J., Smith I. E., O'Brien M. E., et al. Flow cytometric visualisation of cytokine production by CD3–CD56+ NK cells and CD3+CD56+ NK‐T cells in whole blood. Cytometry 2000; 39: 72–8
   PubMedGoogle Scholar
• Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187–376
   PubMed Web of Science ®Google Scholar
• Izumi Y., Ida H., Huang M., Iwanaga N., Tanaka F., Aratake K., et al. Characterization of peripheral natural killer cells in primary Sjögren's syndrome: impaired NK cell activity and low NK cell number. J Lab Clin Med 2006; 147: 242–9
   PubMed Web of Science ®Google Scholar
• Viallard J. F., Pellegrin J. L., Ranchin V., Schaeverbeke T., Dehais J., Longy‐Boursier M., et al. Th1 (IL‐2, interferon‐gamma (IFN‐gamma) and Th2 (IL‐10, IL‐4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999; 115: 189–95
   PubMed Web of Science ®Google Scholar
• Itoh K., Hirohata S. The role of IL‐10 in human B cell activation, proliferation, and differentiation. J Immunol 1995; 154: 4341–50
   PubMed Web of Science ®Google Scholar
• Chen W. F., Zlotnik A. IL‐10: a novel cytotoxic T cell differentiation factor. J Immunol 1991; 147: 528–34
   PubMed Web of Science ®Google Scholar
• Lelievre E., Sarrouilhe D., Morel F., Preud'Homme J. L., Wijdenes J., Lecron J. C. Preincubation of human resting T cell clones with interleukin 10 strongly enhances their ability to produce cytokines after stimulation. Cytokine 1998; 10: 831–40
   PubMedGoogle Scholar
• Levy Y., Brouet J. C. Interleukin‐10 prevents spontaneous death of germinal center B cells by induction of the bcl‐2 protein. J Clin Invest 1994; 93: 424–8
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R., Yssel H., Roncarolo M. G., Spits H., de Vries J. E. Interleukin‐10. Curr Opin Immunol 1992; 4: 314–20
   PubMed Web of Science ®Google Scholar
• Banchereau J., Briere F., Liu Y. J., Rousset F. Molecular control of B lymphocyte growth and differentiation. Stem Cells 1994; 12: 278–88
   PubMed Web of Science ®Google Scholar
• De Maeyer E., De Maeyer‐Guignard J. Interferon‐gamma. Curr Opin Immunol 1992; 4: 321–6
   PubMedGoogle Scholar
• Farrar M. A., Schreiber R. D. The molecular cell biology of interferon‐gamma and its receptor. Annu Rev Immunol 1993; 11: 571–611
   PubMed Web of Science ®Google Scholar
• Howard M., O'Garra A., Ishida H., de Waal Malefyt R., de Vries J. Biological properties of interleukin 10. J Clin Immunol 1992; 12: 239–47
   PubMed Web of Science ®Google Scholar
• Bogdan C., Vodovotz Y., Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991; 174: 1549–55
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R., Abrams J., Bennett B., Figdor C. G., de Vries J. E. Interleukin 10 (IL‐10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL‐10 produced by monocytes. J Exp Med 1991; 174: 1209–20
   PubMed Web of Science ®Google Scholar
• van Woerkom J. M., Kruize A. A., Wenting‐van Wijk M. J., Knol E., Bihari I. C., Jacobs J. W., et al. Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjögren's syndrome compared with non‐Sjögren's sicca syndrome. Ann Rheum Dis 2005; 64: 1474–9
   PubMed Web of Science ®Google Scholar